Clinical Trial Update: Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ADU-S100 with pembrolizumab in metastatic or recurrent head and neck cancer was terminated with posted results in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• ADU-S100 (null)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Chinook Therapeutics, Inc. (formerly Aduro) | Conditions: Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-01-03